On November 6, Axsome Therapeutics fell 5.27% in Regular Trading, trading at $129.83 per share, with turnover of $83.65 million.
The latest market backdrop points to a post-earnings reassessment after the company reported third-quarter results above expectations, while RBC Capital Markets lowered its price target to $273 from $295 and maintained an outperform rating.
Axsome Therapeutics reported a third-quarter loss of $0.25 per share, better than consensus estimates of roughly $0.56 to $0.63, while revenue rose to $259.7 million from $171.0 million a year earlier and exceeded expectations near $249 million. Net product sales of Auvelity reached $207.6 million. Recent market commentary also noted that investors are re-evaluating upside after the earnings-driven rally, even as the firm said Axsome could reach profitability in 2027 if Auvelity revenue continues to expand.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments